<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="./css/bootstrap.min.css">
    <link rel="stylesheet" href="./css/all.min.css">
    <link rel="stylesheet" href="./css/fontawesome.min.css">
    <link rel="stylesheet" href="./css/style.css">
    <title>Diabetes 360 eMagazine</title>
</head>
<body>


    <div class="container">
    <div class="main">
        <div class="left">
            <a href="./page-8.html"><img src="./img/prev.png" alt="previous"></a>
        </div>
        <div class="right">
            <a href="./page-10.html"><img src="./img/next.png" alt="next"></a>
        </div>
        
        <header class="pages-header-footer pages-h-f-white">
            <div class="row align-items-center m-0">
                <div class="col-3 header-txt header-txt-black"><p class=" m-0">NEWSLETTER in Diabetes</p></div>
                <div class="col-7 align-content-center"><div class="dark-line"></div></div>
                <div class="col-2"><img src="img/sanofi-logo-black.png" alt=""></div>
            </div>
        </header>
        <div class="article-head">
            <h1 class="headline"><span class="bold">iGlarLixi Provides a Higher Derived Time-in-range
                versus Insulin Glargine 100 U/mL or Lixisenatide in Asian
                Pacific People with Type 2 Diabetes:</span>
                A Post Hoc Analysis</h1>
                <hr>
            <div class="subheader">
                <p class="primary-col">
                    Source: Guo X, Yang W, Zhang J, Dong X, Liu M, Gu S, Lauand F, Li L, Huang Q, Kang L, Souhami E. iGlarLixi provides a higher derived
                    time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes:<br>
                    A post hoc analysis. Diabetes Obes Metab. 2023 Jul;25(7):2005-2011.
                </p>
            </div>
        </div>
        <article>
            <div class="row">
                <div class="col-lg-6 col-sm-12">
                    <div class="feature-img">
                        <img src="./img/magazine-edit-13-3-20.jpg" alt="feature-img">
                    </div>
                    <p>
                        Guo et al., aimed to evaluate the efficacy of iGlarLixi
                        (insulin glargine 100 units/mL / lixisenatide) in the Asian
                        Pacific (AP) population with type 2 diabetes (T2D) using
                        dTIRs calculated from seven-point self measured blood
                        glucose.
                    </p>
                       
                    <h3 class="h3-inner">Two phase III trials were analyzed.</h3>
                        <p>
                            - The participants of the LixiLan-O-AP (NCT03798054)
                            and LixiLan-LCN (NCT03798080) studies were included.<br>
                            - In the LixiLan-O-AP study (n=878), insulin-naive AP
                            patients (86.3% of whom were from mainland China)
                            with suboptimally controlled T2D were randomized
                            (2:2:1) to receive iGlarLixi, iGlar or Lixi once a day on top
                            of continued metformin with or without sodium-glucose
                            co-transporter-2 inhibitors.<br>
                            - The LixiLan-LCN study (n=426) included Chinese patients
                            with T2D uncontrolled on basal insulin, randomized (1:1)
                            to iGlarLixi or iGlar on top of continued metformin if
                            applicable.<br>
                            - Changes in derived time-in-ranges from baseline to endof-
                            treatment (EOT) and estimated treatment differences
                            (ETDs) were analyzed.
                        </p>

    
                </div>
    
                <div class="col-lg-6 col-sm-12">
                    <p>
                        - The proportions of patients achieving 70% or higher
                        derived time-in-range (dTIR), 5% or higher dTIR
                        improvement, and the composite triple target (≥70%
                        dTIR, &lt;4% derived time-below-the-range [dTBR] and
                        &lt;25% derived timeabove- the-range [dTAR]) were
                        calculated.
                    </p>
                    <p>
                        iGlarLixi achieved greater improvements in derived
                        time-in-ranges than iGlar or Lixi without increasing
                        the risk of hypoglycaemia. The results of this post hoc
                        analysis, in addition to previous results of the LixiLan
                        study programme, support the use of iGlarLixi as an
                        efficacious option for both insulin-naive and basal
                        insulinexperienced AP people with suboptimally
                        controlled T2D.
                    </p>
                    
                    <div class="purple-quote primary-bg">
                        <div class="quotes"><img src="./img/quotes.png" alt=""></div>
                        <h3>Conclusion</h3>
                        <p>
                            This post hoc analysis showed that iGlarLixi is
                            an effective treatment option to improve
                            dTIR and dTTR in insulin-naïve and insulinexperienced
                            AP people with T2D. <br>
                            The proportions of patients achieving 70% or
                            higher dTIR, 5% or higher dTIR improvement
                            and the triple target were higher with iGlarLixi
                            than with iGlar or Lixi.<br>
                            In addition, iGlarLixi reduced dTAR without
                            increasing hypoglycemic exposure, as indicated
                            by the low dTBR values. The insulin glargine
                            component of iGlarLixi ensures glucose
                            control in the fasting state and at night, while
                            the lixisenatide component decreases the
                            postprandial excursions.<br>
                            This analysis showed that iGlarLixi increased
                            the proportion of patients with 70% or higher
                            dTIR to achieve glycemic goals.
                        </p>
                    </div>
                    
                </div>
            </div>
            
            <div class="article-footer">
                <div class="row">
                    <div class="col-lg-6 col-sm-12">
                        <div class="ref-rating">
                            <p>
                                T2D, type 2 diabetes; AP, Asian pacific; dTIR, derived time-in-range;
                                dTBR, derived time-below-range; dTAR, derived time-above-range
                            </p>                    
                        </div>
                        <div class="rating">
                            <p>How do you rate this article?</p>
                            <div class="row px-4">
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=1" target="_blank"><img src="./img/red-1.png" alt="rate1"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=2" target="_blank"><img src="./img/orange-2.png" alt="rate2"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/mustard-3.png" alt="rate3"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=4" target="_blank"><img src="./img/yellow-4.png" alt="rate4"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=5" target="_blank"><img src="./img/green-5.png" alt="rate5"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=6" target="_blank"><img src="./img/turquoise-6.png" alt="rate6"></a></div>
                                <div class="col p-1"><a href="https://dta.eu.qualtrics.com/jfe/form/SV_efWbOu2lUz2aZpQ?CO=EG&Q_Language=EN&Brand=Unbranded&CN=Diabetes_360_eMagazine&Channel=E-NewsLetter&Function=Medical&Franchise=Diabetes_Core&TA=Diabetes&DA=Type_2_Diabetes&R=3" target="_blank"><img src="./img/aquamarine-7.png" alt="rate7"></a></div>
                            </div>
                            <div class="rating-bar">
                                <img src="./img/rating-1-5.png" alt="">
                            </div>  
                        </div>
                    </div>
                </div>
            </div>
        </article>
        </div>
        <footer class="footer">
            <div class="pages-header-footer">
                <div class="row">
                    <div class="col-1">
                        <div class="pagination">
                            <p>9</p>
                        </div>
                    </div>
                    <div class="col-8 align-content-center p-0">
                        <div class="dark-line"></div>
                    </div>
                    <div class="col-3 d-flex justify-content-center align-items-center">
                        <div class="header-txt-black header-txt">The 360 e-Magazine</div>
                    </div>
                </div>
            </div>
        
    </footer>

        </div>

    </div>    
    </div>


    <script src="./js/bootstrap.bundle.min.js"></script>
    </body>
</html>